From the Guidelines
The Havrix vaccine dosage is based on age, not weight, with 720 EL.U/0.5 mL for children and adolescents aged 1-18 years, and 1440 EL.U/1 mL for adults 19 years and older. The dosage recommendations are supported by the most recent evidence from the Centers for Disease Control and Prevention (CDC) 1.
Key Points
- The pediatric formulation of Havrix is 720 EL.U/0.5 mL, administered in a 2-dose schedule for children and adolescents aged 1-18 years.
- The adult formulation of Havrix is 1440 EL.U/1 mL, administered in a 2-dose schedule for adults 19 years and older.
- The weight-based dosing is not explicitly recommended, but rather age-based dosing.
- Administration of Havrix should be as an intramuscular injection in the deltoid muscle for adults and older children, or in the anterolateral thigh for younger children.
- Common side effects include soreness at the injection site, headache, and fatigue, which typically resolve within a few days.
Administration
When administering Havrix, it is essential to follow the recommended schedule and dosage to ensure optimal immune response and minimize side effects. The CDC recommendations 1 provide guidance on the administration of Havrix for different age groups and risk categories.
Evidence
The evidence from the CDC 1 and other studies 1 supports the use of Havrix vaccine in preventing hepatitis A infection. However, the most recent and highest-quality study 1 should be prioritized when making recommendations.
From the Research
Havrix Dosage by Weight
The Havrix (Hepatitis A vaccine) dosage is not directly specified by weight in the provided studies. However, the following information is available:
- For patients 2-18 years of age, the recommended dose is 0.5 mL (720 ELISA units) 2.
- For adults, the recommended dose is 1.0-mL (1440 ELISA units) 2, 3.
- There is no specific dosage recommendation by weight, but rather by age group.